CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 69 enrolled
Drug / intervention
Interleukin-2drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00003126
NCT00003126Phase 3Completed
CompareCT.gov

A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma

Loyola University·interventional·Posted Oct 28, 2003·Updated Jan 4, 2017

In Brief

A Phase 3 clinical trial evaluating Interleukin-2 for Kidney Cancer. Completed, enrolled 69 participants across 15 sites.

Detailed Summary

The purpose of this study is to assess the efficacy of post-operative high-dose bolus interleukin-2 (IL-2) in patients with high-risk renal cell carcinoma (RCC).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Cancer
CountriesUnited States
CollaboratorsChiron Corporation

Timeline

Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 28, 2003
Enrollment StartJun 1, 1997
Primary CompletionAug 1, 2002
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 22.7 years ago

Interventions

Interleukin-2drug

High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC